Back to today’s briefing

Story perspectives

Psilocybin Dose Offers Hope for Cancer Patients' Depression

7/6/2025

41 3

Summary

Story summary

A groundbreaking clinical trial in the CANCER journal shows that a single 25-mg dose of psilocybin can dramatically alleviate depression and anxiety in cancer patients battling major depressive disorder. Remarkably, after two years, over half of the participants reported reduced depression, while nearly 43% felt less anxious. Excitingly, ongoing trials are set to explore the effects of repeated doses for even greater relief.

1 of 1

Story summary

A groundbreaking clinical trial in the CANCER journal shows that a single 25-mg dose of psilocybin can dramatically alleviate depression and anxiety in cancer patients battling major depressive disorder. Remarkably, after two years, over half of the participants reported reduced depression, while nearly 43% felt less anxious. Excitingly, ongoing trials are set to explore the effects of repeated doses for even greater relief.